Current Report Filing (8-k)
December 28 2022 - 5:01PM
Edgar (US Regulatory)
0001769804
false
0001769804
2022-12-21
2022-12-21
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): December 21, 2022
AUGMEDIX,
INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-40890 |
|
83-3299164 |
(State or other jurisdiction
of
incorporation) |
|
(Commission
File Number) |
|
(I.R.S.
Employer
Identification
No.) |
111 Sutter Street, Suite 1300, San Francisco, California 94104
(Address
of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code: (888) 669-4885
N/A
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common Stock, $0.0001 par value per share |
|
AUGX |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
1.01. Entry into a Material Definitive Agreement
On
December 21, 2022, Augmedix Solutions Pvt. Ltd. (the “Tenant”), which is an indirect wholly-owned subsidiary
of Augmedix, Inc., a Delaware corporation (the “Company”), entered into an agreement to lease (the “Lease”)
with Shukoor Habib Trust and Rafeeq Trust (collectively, the “Landlord”) for Office Unit No. 2 on the Third
Floor of MFAR SILVERLINE TECHPARK, a property located at Industrial Plot No. 180 of EPIP, II Phase, Whitefield, Bangalore (formed in
portion of Survey No. 28, Kundalahalli Village, K.R. Puram Hobli, Bangalore East Taluk) (the “Premises”). The
Premises comprises approximately 13,500 rentable square feet.
The
Lease term is for a period of five (5) years, commencing on January 1, 2023. The Tenant and Landlord are not entitled to terminate the
lease for an initial period of thirty-six (36) months except for termination due to a material breach or a force majeure event (the “Lock-in
Period”). The Tenant may terminate the lease by providing ninety (90) days’ advance written notice prior to the end
of the Lock-in Period or any time after the Lock-in Period concludes. The parties may renew the Lease on such terms and conditions as
mutually agreed between the parties.
The
monthly rental rate for the period between January 1, 2023 to December 31, 2024 is 7,56,000 Rupees (“Rs.”),
for the period between January 1, 2025 to December 31, 2026 is 7,93,800 Rs. and for the period between January 1, 2027 to December 31,
2027 is 8,33,490 Rs. The Tenant is also required to pay maintenance charges as they become due.
The
Lease is furnished as Exhibit 10.1 to this current report on Form 8-K and is incorporated herein by reference. The foregoing description
of the Lease does not purport to be complete and is qualified in its entirety by reference to the Lease.
Item
9.01. Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
AUGMEDIX,
INC. |
|
|
|
Dated:
December 28, 2022 |
By:
|
/s/
Paul Ginocchio |
|
|
Paul
Ginocchio |
|
|
Chief
Financial Officer |
2
Augmedix (NASDAQ:AUGX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Augmedix (NASDAQ:AUGX)
Historical Stock Chart
From Apr 2023 to Apr 2024